Bipolar depression: Best practices for the outpatient

CNS Spectrums

Volumn 12, Issue 12 SUPPL., 2007, Pages 1-15

  Keck Jr , Paul E ^a,b   McIntyre, Roger S ^b,c,d   Shelton, Richard C ^e,f,g  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

^c UNIVERSITY OF TORONTO   (Canada)

^d University Health Network

^e VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^f JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^g BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; FLUOXETINE; HYPERICUM PERFORATUM EXTRACT; IMIPRAMINE; LAMOTRIGINE; LITHIUM; LORAZEPAM; OLANZAPINE; PAROXETINE; PLACEBO; QUETIAPINE; SERTRALINE; VALPROATE SEMISODIUM; VENLAFAXINE; ZOLPIDEM;

ANXIETY; BEDTIME DOSAGE; BEHAVIOR DISORDER; BIPOLAR DEPRESSION; BIPOLAR I DISORDER; CLINICAL PRACTICE; CLINICAL TRIAL; COGNITIVE THERAPY; COMBINATION CHEMOTHERAPY; COMORBIDITY; CONFERENCE PAPER; CONTROLLED STUDY; CYCLING; DIAGNOSTIC ERROR; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; FUNCTIONAL DISEASE; GROUP THERAPY; HUMAN; HYPERICUM PERFORATUM; HYPOMANIA; INSOMNIA; LONG TERM CARE; MANIA; MONOTHERAPY; PATIENT CARE; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOPHRENIA; SUICIDE ATTEMPT;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DRUG RESISTANCE; HUMANS; MENTAL HEALTH SERVICES; PERIODICITY;

EID: 38049019012     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (19)

1. Judd LL, Akiskal HS, Schettler PJ, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry. 2002;59(6):530-537.
2. Judd LL, Akiskal HS, Schettler PJ, et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry. 2003;60(3):261-269.
3. Judd LL, Akiskal HS, Schettler PJ, et al. Psychosocial disability in the course of bipolar I and II disorders: a prospective, comparative, longitudinal study. Arch Gen Psychiatry. 2005;62(12):1322-1330.
4. Gijsman HJ, Geddes JR, Rendell JM, Nolen WA, Goodwin GM. Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. Am J Psychiatry. 2004;161(9):1537-1547.
5. Nemeroff CB, Evans DL, Gyulai L, et al. Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am J Psychiatry. 2001;158(6):906-912.
6. Post RM, Altshuler LL, Leverich GS, et al. Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline. Br J Psychiatry. 2006;189:124-131.
7. Sachs GS, Nierenberg AA, Calabrese JR, et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. NEJM. 2007;356:1711-1722.
8. Calabrese JR, Bowden CL, Sachs GS, Ascher JA, Monaghan E, Rudd GD, and the Lamictal 602 Study Group. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. J Clin Psychiatry. 1999;60(2):79-88.
9. Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry. 2003;60(11):1079-1088.
10. Corya SA, Perlis RH, Keck PE Jr, et al. A 24-week open-label extension study of olanzapine-fluoxetine combination and olanzapine monotherapy in the treatment of bipolar depression. J Clin Psychiatry. 2006;67(5):798-806.
11. Shi L, Namjoshi MA, Swindle R, et al. Effects of olanzapine alone and olanzapine/fluoxetine combination on health-related quality of life in patients with bipolar depression: secondary analyses of a double-blind, placebo-controlled, randomized clinical trial. Clin Ther. 2004;26(1):125-134.
12. Calabrese JR, Keck PE Jr, Macfadden W, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry. 2005;162(7):1351-1360.
13. Thase ME, Macfadden W, Weisler RH, et al, and the BOLDER II Study Group. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol. 2006;26(6):600-609.
14. Nierenberg AA, Ostacher MJ, Calabrese JR, et al. Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. Am J Psychiatry. 2006;163(2):210-216.
15. Goodwin FK, Jamison KR. Manic-Depressive Illness. New York, NY: Oxford University Press; 1990.
16. Wehr TA, Goodwin FK. Can antidepressants cause mania and worsen the course of affective illness? Am J Psychiatry. 1987;144(11):1403-1411.
17. Gijsman HJ, Geddes JR, Rendell JM, Nolen WA, Goodwin GM. Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. Am J Psychiatry. 2004;161(9):1537-1547.
18. Angst J, Gamma A, Benazzi F, Ajdacic V, Eich D, Rossler W. Toward a re-definition of subthreshold bipolarity: epidemiology and proposed criteria for bipolar-II, minor bipolar disorders and hypomania. J Affect Disord 2003;73:133-146.
19. Suppes T, Dennehy EB, Hirschfeld RM, et al, and the Texas Consensus Conference Panel on Medication Treatment of Bipolar Disorder. The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. J Clin Psychiatry. 2005;66(7):870-886.